3 ETFs set to soar in the second half of 2013
Look to areas like biotech and financials for growth right now.
The narrative on Wall Street during the past few months has been one of volatility and uncertainty. The popular momentum trades of the year -- including hot emerging markets or the Nikkei/Yen trade -- have lost steam in a hurry.
So what's next as we look for new leadership? Well, it's hard to tell. It could be U.S. megacaps as the market gets defensive after front-loaded returns. If the global economy rounds the bend, it could be the battered markets of Europe. Or it could be some corner of Wall Street that we aren't even watching yet.
With such a cloudy outlook, then, it behooves investors to start thinking longer-term and lower-risk. And the easiest way to take on that kind of strategy is to buy diversified ETFs that fit well with the current headlines and that will be resilient against just about anything the market will throw our way.
To help you rebalance your portfolio for the second half of 2013 and beyond, here are a few ETFs that investors should consider staking out a position in right now:
iShares Nasdaq Biotechnology Index Fund
The iShares NASDAQ Biotechnology Index Fund (IBB) is a great way to both play upstart drugmakers and get exposure to bigger players for some stability.
For instance, the top three IBB holdings as of June 19 are Regeneron (REGN), Gilead Sciences (GILD) and Amgen (AMGN) -- a trifecta worth about $175 billion. These are hardly up-and-coming players, with all running very profitable operations and no risk of going to zero on one bad drug trial. However, it also has a stake in smaller players that will break out, like Isis Pharmaceuticals (ISIS), which has more than doubled since Jan. 1.
All told, the IBB fund is up an impressive 26% year-to-date -- almost double the S&P 500 -- and is up about 36% in the last 12 months.
Given the demographic pressured fueling healthcare generally -- driven by aging baby boomers -- and the specific potential of niche drugs and breakthrough medical technology, all investors should look to this sector for growth. And given that healthcare also is a (mostly) recession-proof sector, any downturn shouldn't hit IBB too badly in the months ahead.
With almost $3.1 billion in assets and a six-digit daily trading volume, this is a legit and liquid fund. IBB will cost you 0.48% in expenses (that's $48 in fees annually for $10,000 invested). (Learn more on the iShares website.)
If you're looking to stake out a claim in the recovery, financial stocks are a very good bet right now. Thus, the Financial SPDR (XLF) should be on your radar during the second half of 2013.
Why? For starters, financial stocks are inherently cyclical in nature; they do best when the economy is humming along, which causes investment and lending to hum along, too.
Also, the fundamentals still are cheap. Compared with other sectors, banks remain undervalued based on forward earnings. Investors have been discounting bank shares since the financial crisis for obvious reasons, but this can't last forever.
Also remember that dividends have remained pretty anemic in the sector thanks to the red tape of the Federal Reserve "stress tests," so there's the potential for payouts to move up significantly in the years ahead. Consider that Bank of America (BAC) and Citigroup (C) pay a nominal penny per quarter on each share of stock. That can and will move upward.
There is the risk that a downturn could hurt banks, of course, but the XLF is focused on major financial institutions and shouldn't see the same risk as regionals or smaller banks. After all, there have been many complaints about "too big to fail" … but the hard truth is that major financials cannot and will not be allowed to collapse no matter what happens in the next few years. That's just the way it is.
With a very low expense ratio of 0.18%, or just $18 on $10,000 invested, this is a great way to play the sector. (Check out more on the SPDR website.)
Vanguard Energy ETF
Another cyclical play -- this time with an eye toward inflationary pressures that might take hold in 2014 or beyond -- is the Vanguard Energy ETF (VDE).
With top holdings in megacaps like Exxon Mobil (XOM) and Chevron (CVX), investors can be confident in the stability of this fund should the market run into trouble. They all pay decent dividends, too, and will provide a bit of income.
The energy sector provides some pop longer-term for folks betting on a recovery improving demand for fossil fuels, as well as those expecting high federal deficits and the chance of a weaker dollar in 2014 to boost inflation. Right now inflation is handily under control, but farther down the road it could be a problem and result in rising crude oil prices -- and thus profits across the energy sector rising in kind.
Total assets of VDE top $2.6 billion and the expense ratio -- like always in Vanguard's family of funds -- is very low. This energy ETF charges just 0.14% in expenses, or $14 per $10,000 invested. (Learn more about VDE on Vanguard's website.)
For two more funds that should soar in the second half of the year, click here.
Jeff Reeves is the editor of InvestorPlace.com and the author of “The Frugal Investor’s Guide to Finding Great Stocks.” Write him at firstname.lastname@example.org or follow him on Twitter via @JeffReevesIP. As of this writing, he did not hold a position in any of the stocks named here.
More from InvestorPlace
MORE ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The photo-sharing site only has 10 employees, and it may be up for grabs.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.